Albendazol 200 mg
dc.contributor.author | Caja Costarricense de Seguro Social, Departamento y Comité Central de Farmacoterapia | |
dc.date.accessioned | 2024-04-29T15:33:00Z | |
dc.date.available | 2024-04-29T15:33:00Z | |
dc.date.issued | 2002-09-17 | |
dc.identifier.uri | http://hdl.handle.net/20.500.11764/4257 | |
dc.description | CIRCULAR | es_ES |
dc.description.abstract | Albendazol 200 mg | es_ES |
dc.description.sponsorship | CCSS | es_ES |
dc.language.iso | es | es_ES |
dc.publisher | CCSS | es_ES |
dc.subject | ALBENDAZOL | es_ES |
dc.title | Albendazol 200 mg | es_ES |
dc.type | Working Paper | es_ES |
Files in this item
This item appears in the following Collection(s)
-
Farmacoepidemiología
Informes técnicos, sobre investigación de medicamentos en la CCSS